Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.98 USD | -2.21% | -11.16% | -24.48% |
03-13 | Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating | MT |
03-12 | Transcript : Bioventus Inc., Q4 2023 Earnings Call, Mar 12, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.48% | 254M | C | ||
+73.17% | 12.38B | B- | ||
-18.74% | 7.92B | C+ | ||
+16.15% | 7.2B | C- | ||
+4.81% | 5.84B | B | ||
+5.99% | 5.07B | D+ | ||
+27.07% | 4.53B | - | ||
-21.67% | 3.88B | B- | ||
-40.82% | 2.23B | C | ||
+1.49% | 2.02B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BVS Stock
- Ratings Bioventus Inc.